$HUM

Humana Will Drop 37 PPOs for 2027. If Her Plan Is Discontinued, She Can Get a Medigap Window Without Health Questions Even if Humana Offers Another Advantage Plan

Humana (HUM) is discontinuing 37 PPO Medicare Advantage plans in 2027, offering HMOs and special needs plans instead. Affected members have a 63-day window to enroll in Medigap without health questions, according to federal rules. Humana expects to retain about 40% of members in other plans. Members must choose between Humana's HMO or Original Medicare with Medigap and Part D, considering network, costs, and health needs.

Original reporting
Published Oct 15, 2026, 4:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 15, 2026, 4:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Humana Will Drop 37 PPOs for 2027. If Her Plan Is Discontinued, She Can Get a Medigap Window Without Health Questions Even if Humana Offers Another Advantage Plan — source image
Decision brief

The 30-second read

$HUMNeutralLow
01

Why it matters

For traders, the key takeaway is that Humana’s PPO reductions may increase the share of members who can switch to Original Medicare plus Medigap without underwriting, potentially affecting retention and risk mix.

02

Market read

This is a member-rights and plan-exit explainer with one concrete company-specific disclosure (37 PPOs dropped for 2027), relevant mainly for retention and churn expectations.

03

What to watch

The article focuses on member decision rights and does not quantify actual churn, premium changes, or the financial magnitude of the PPO exits, so market impact may be smaller than the narrative suggests.

Relevance 4/10Novelty 4/10Timing: this fall, when affected members receive termination notices and Medigap guaranteed-issue windows begin

Background

The article describes Humana’s Medicare Advantage PPO plan exits for 2027 and explains federal guaranteed-issue Medigap rules when an MA plan is not renewed or leaves a service area.

Company-level read

Ticker impact

$HUMNeutralMedium confidence
Context

Humana is dropping 37 PPO plans for 2027 and the article explains how plan non-renewal can trigger a Medigap guaranteed-issue window for affected members.

Expected impact

Likely modest negative bias as investors weigh higher churn risk from PPO exits, partially offset by the stated goal to recapture about 40% of affected members into other Humana plans.

Evidence & confidence

The piece is primarily an explainer of member rights and decision-making, but it does disclose Humana’s PPO plan reduction for 2027 and quantifies a recapture expectation, both directly tied to retention dynamics.

Market effects

Highlights Medicare Advantage plan exit mechanics and Medigap guaranteed-issue rules, which can affect competitive retention strategies across MA insurers.

US-wide relevance for Medicare Advantage beneficiaries, with impact varying by state Medigap protections and Humana’s market exits.

limited, as the story is US healthcare insurance policy and plan design.

Counterpoint

The recapture target (about 40%) and the shift toward HMOs and special needs plans could improve margin quality, making the net impact less negative than churn fears imply.

Key entities

  • Humana

    Medicare Advantage insurer dropping 37 PPO plans for 2027 and expecting to recapture about 40% of affected members into other Humana plans.

Related articles

$HUMMed

Humana’s $2.8 bn BlackRock deal follows Medicare Advantage ratings recovery

Humana (HUM) agreed to a $2.8 bn deal with BlackRock, restructuring ownership of 150 CenterWell clinics. BlackRock acquires WCAS's majority stake, with Humana retaining minority ownership. The deal reduces Humana's balance sheet obligations. Humana's Medicare Advantage star ratings improved, potentially increasing 2028 bonus payments to $4.8 bn, per Evercore ISI. S&P affirmed Humana's BBB rating but maintained a negative outlook.

$HUMMedAI 9/10

Seniors at About 150 CenterWell Clinics Face New Majority Owner as BlackRock Replaces Private Equity Backer

Humana announced that BlackRock's HPS Investment Partners will acquire Welsh Carson's stake in about 150 CenterWell clinics, valued at $2.8B. The deal, expected to close in Q4 2026, will make BlackRock the majority owner, with CenterWell retaining a minority stake and operational control. Humana stated patient care will remain unchanged, and the deal is not expected to materially affect its 2026 earnings guidance.

$HUMMedAI 8/10

Humana, BlackRock Strike $2.8 Bn Deal for CenterWell Clinics

Humana and BlackRock's HPS Investment Partners will form a joint venture to operate and expand CenterWell clinics, with BlackRock acquiring WCAS's stake for $2.8B. The deal aims to provide growth capital and lower costs for Humana, with no disruption to patient care. Humana may repurchase clinics starting 2028. The transaction is expected to close in Q4 2026, with no impact on 2026 earnings guidance.

$HUMMed

What Humana’s BlackRock Deal, Village Medical’s Divestitures Signal For Older Adult Primary Care

Humana (NYSE: HUM) announced a joint venture with BlackRock to manage 150 CenterWell clinics, while Village Medical divested 27 clinics to Harbor Health. These moves suggest a shift in the senior-focused primary care industry, with changes in ownership and financing strategies. Humana's deal includes a $2.8 billion equity acquisition and potential clinic purchases by CenterWell starting in 2028.

$HUMMedAI 8/10

Humana's CenterWell Expansion Gets a Boost From BlackRock's Capital

Humana (HUM) is forming a joint venture with BlackRock to own 150 CenterWell clinics, valued at $2.8B. BlackRock will hold majority ownership, with Humana retaining minority. The deal, expected to close in Q4 2026, will reduce Humana's liabilities and support clinic expansion. Humana's 2026 earnings guidance remains at least $9 per share.

$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.